



FAX COVER SHEET

The information contained in this facsimile message, if a client of this firm is a named addressee, or the message is otherwise intended for a client, is presumptively legally privileged and confidential information. If you are not a named addressee, or if there is any reason to believe that you may have received this message in error, (1) do not read the message below; (2) do not distribute or copy this facsimile; and (3) please immediately call us collect at the number of the sender below.

DATE:	September 30, 2003	TOTAL # OF PAGES: (INCLUDING THIS COVER SHEET)	5
TO:	Examiner Janice Q. Li	FAX #:	703-872-9306
FIRM NAME:	USPTO	PHONE #:	703-308-7942
FROM:	Euk Y. Oh, Reg. No. 54,345	FAX #:	(415) 398-3249
PHONE #:	(415) 781-1989	EMAIL:	oh.charlie@dorseylaw.com

COMMENTS:

To: Examiner Janice Q. Li

For: US Patent Application Ser. No. 09/515,582

Title: Methods for Enhancing Graft Survival by Modulating Heme-Oxygenase Activity

Enclosures:

- (1) Supplemental IDS (2 pages)
- (2) Substitute for Form 1449 (2 pages)

ORIGINAL WILL BE SENT VIA: MAIL E-MAIL MESSENGER AIR COURIER WILL NOT BE SENT

PLEASE CONTACT CHARLIE Y. OH, PH.D. AT (415) 781-1989 IF THIS TRANSMISSION IS INCOMPLETE OR CANNOT BE READ.

REFERENCE #

DORSEY & WHITNEY LLP • WWW.DORSEY.COM • T. 415.781.1989 • F. 415.398.3249
FOUR EMBARCADERO CENTER • SUITE 3400 • SAN FRANCISCO, CALIFORNIA 94111-4187

USA CANADA EUROPE ASIA

PATENT

Attorney Docket No.: A-63708-5/RFT/TAL/CYO
 Attorney Client Matter No.: 465840-00245

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re application of:**BUELOW *et al.*

Serial No. 09/515,582

Filed: February 29, 2000


For: **METHODS FOR ENHANCING
GRAFT SURVIVAL BY
MODULATING HEME
OXYGENASE ACTIVITY**

Examiner: Li, Qian J.

Art Group No. 1632

CERTIFICATE OF FAX TRANSMISSION

I hereby certify that this correspondence, including listed enclosures, is being FAX transmitted to USPTO FAX No. (703) 872-9306 on:

Date: September 30, 2003Signature 
Euk Oh**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to make formally of record in this case references cited on the accompanying Substitute for Form 1449. Copies of references C1-C13 were provided by Applicants in the response filed June 26, 2002. Accordingly, copies of references are not enclosed.

None of the foregoing references are believed to disclose the invention as claimed. Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

RECEIVED
 CENTRAL FAX CENTER

OCT 01 2003

OFFICIAL

1120939_1.DOC

Received from <415 398 3249> at 9/30/03 4:57:29 PM [Eastern Daylight Time]

USSN: 09/515,582
Filing Date: February 29, 2000

The Commissioner is authorized to charge any necessary fees which may be required, including any required fees under 37 CFR § 1.97, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. A-63708-5 (465840-00245)/RFT/TAL/CYO).

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY, LLP

Dated: February 20, 2003

By: Euk Y. Oh

Customer No.: 32940
Dorsey & Whitney LLP
Four Embarcadero Center, Suite 3400
San Francisco, California 94111-4187
Telephone: (415) 781-1989
Fax No. (415) 398-3249

Euk Y. Oh, Reg. No. 54,345 for
Todd A. Lorenz, Reg. No. 39,754

Filed under 37 C.F.R. § 1.34(a)

RECEIVED
CENTRAL FAX CENTER

OCT 01 2003

OFFICIAL

Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Complete if Known	
Sheet	1	of	2	Application Number	09/515,582
				Filing Date	02/29/2000
				First Named Inventor	Buelow, R.
				Group Art Unit	1632
				Examiner Name	Li, Q. J.
				Attorney Docket Number	A-63708-5/TAL/CYO

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1					
A2					
A3					
A4					
A5					
A6					
A7					
A8					
A9					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
B1						
B2						
B3						
B4						
B5						
B6						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
C1	Evans, C-O et al., "Cloning and sequencing and expression of cDNA for chick liver haem oxygenase: comparison of avian and mammalian cDNAs and deduced protein," <i>Biochem J.</i> 273:659-666 (1991).		
C2	Yoshida, et al., "Human heme oxygenase cDNA and induction of its mRNA by hemin," <i>Eur. J. Biochem.</i> 171:457-461 (1988)		
C3	Ishikawa, K. et al., "Expression of rat heme oxygenase in Escherichia coli as a catalytically active, full length form that binds to bacterial membranes," <i>Eur. J. Biochem.</i> 202:161-165 (1991).		
C4	Schmitt, M.P., Utilization of Host Iron Sources by Corynebacterium diphtheriae: Identification of a Gene Whose Product Is Homologous to Eukaryotic Heme Oxygenases and Is Required for Acquisition of Iron from Heme and Hemoglobin," <i>J. Bact.</i> 179(5):838-845 (1997)		
C5	Rotenberg, M.O. et al., "Characterization of a cDNA-Encoding Rabbit Brain Heme Oxygenase-2 and Identification of a Conserved Domain among Mammalian Heme Oxygenase Isozymes: Possible Heme-Binding Site," <i>Archive Biochem. Biophys.</i> 290(2) 336-344 (1991)		

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1120936_1.DOC

Substitute PTO/SB/8A (06-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Compleat if Known
Sheet	2	of	2	Attorney Docket Number
				A-63708-5/TAL/CYO

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ^o
C8	Wilks, A. et al., "Rat Liver Heme Oxygenase: High Level Expression of a Truncated Soluble Form and Nature of the Meso-Hydroxylating Species," <i>J. Biol. Chem.</i> 268:22357-62 (1993)		
C7	Schuller, D.J. "Crystal structure of heme oxygenase-1," <i>Nature Struct. Biol.</i> 6(9):860-867 (1999).		
C8	Omata, Y. et al., "Crystallization and preliminary X-ray diffraction studies on the water soluble form of rat heme oxygenase-1 in complex with heme," <i>Acta Cryst. D54</i> :1017-1019 (1998).		
C9	Hegazy, K.A. et al., "Functional human heme oxygenase has a neuroprotective effect on adult rat ganglion cells after pressure induced ischemia," <i>Regeneration and Transplantation</i> 11(6):1185-1189 (2000)		
C10	Melo, L.G. et al., "Gene Therapy Strategy for Long-Term Myocardial Protection Using Adeno-Associated Virus Mediated Delivery of Heme Oxygenase Gene," <i>Circulation</i> 105:602-607 (2002)		
C11	Juan, S-H. et al., Adenovirus-Mediated Heme Oxygenase-1 Gene Transfer Inhibits the Development of Atherosclerosis in Apolipoprotein E-Deficient Mice," <i>Circulation</i> 104:1519-1525 (2001).		
C12	Lee, P.J. et al., "Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia," <i>Proc. Natl. Acad. Sci. USA</i> 93:10393-10398 (1996).		
C13	Hori, R. et al., "Gene Transfection of H25A Mutant Heme Oxygenase-1 Protects Cells against Hyperoxide-Induced Cytotoxicity," <i>J. Biol. Chem.</i> 277(12):10712-10718 (2002).		
C14			
C15			
C16			
C17			
C18			
C19			
C20			
C21			
C22			
C23			
C24			
C25			
C26			
C27			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 18 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1120936_1.DOC